Century Therapeutics, Inc. filed a current report on September 9, 2026, disclosing the appointment of Joseph Truitt as a new member of its Board of Directors, effective the same date.
Key Highlights
- Board expanded: The Board increased its size from six to seven directors upon Truitt's appointment.
- Class I director: Truitt will serve as a Class I director with a term expiring at the 2028 Annual Meeting of Stockholders.
- Committee assignment: Truitt will serve as a member of the Compensation Committee of the Board.
- Initial equity grant: Truitt will receive an option to purchase 148,000 shares of common stock, vesting in equal monthly installments over 36 months from the effective date.
- Annual cash retainer: Truitt is entitled to an annual cash retainer of $40,000 as a Board member.
- Independence determination: The Board determined that Truitt is an independent director under applicable Nasdaq listing rules.
Joseph Truitt Joins Century Therapeutics Board With Biopharma Leadership Background
According to the filing, Century Therapeutics, Inc. (NASDAQ:IPSC), a Delaware corporation headquartered in Philadelphia, Pennsylvania, appointed Joseph Truitt, age 62, to its Board of Directors on September 9, 2026. The appointment followed a recommendation from the Nominating and Corporate Governance Committee. Truitt's compensation will be governed by the Company's Non-Employee Director Compensation Policy, and the Company entered into an indemnification agreement with him in substantially the same form as those entered into with other directors.
The filing describes Truitt's current role as Chief Executive Officer of iECURE, Inc., a gene editing company, a position he has held since March 2021. He has also served on the board of Larimar Therapeutics, Inc. (Nasdaq: LRMR) since May 2020 and as a director of Code Biotherapeutics, Inc. since December 2020. Previously, according to the filing, Truitt served as President, Chief Executive Officer, and board member of Achillion Pharmaceuticals, Inc. from May 2018 until April 2020, and as Chief Executive Officer of BioSpecifics Technologies Corp. from April 2020 through December 2020.
The filing also notes that Truitt held roles including Vice President, Business Development and Product Strategy at Lev Pharmaceuticals, Inc., and Vice President, Sales and Operations at Johnson and Johnson - OraPharma, Inc. He received a B.S. in Marketing from La Salle University and an M.B.A. from St. Joseph's University in Pharmaceutical Marketing, and previously served as a Captain in the United States Marine Corps. The filing states there are no family relationships between Truitt and any directors or executive officers of the Company, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
What Was Disclosed
Century Therapeutics reported the expansion of its Board from six to seven members and the appointment of Joseph Truitt as a Class I independent director, along with his compensation terms including a 148,000-share option grant and a $40,000 annual cash retainer.






Please wait processing your request...